Women, 2006
18 women, one 20 mg intranasal dose, crossover design
Premenopausal women with female sexual arousal disorder received a single 20 mg intranasal dose and placebo in separate in-clinic sessions. More women reported moderate or high sexual desire after bremelanotide than after placebo (P = 0.0114). Among those who attempted intercourse within 24 hours, significantly more were satisfied with their level of arousal (P = 0.0256). Vaginal vasocongestion did not change significantly.
Diamond LE et al. J Sex Med. 2006;3(4):628-638. A research formulation at a research dose, not the Rebody bottle.











